LONDON, UK: Merck, a global leader in biopharmaceuticals, has announced that it has entered into a definitive agreement to acquire Caraway Therapeutics, Inc., a company specialized in developing novel, small-molecule therapeutics for the treatment of neurodegenerative and rare diseases. The deal is worth up to $610 million, including an undisclosed upfront payment and contingent milestone…